Skip to content
BiologicalX

Comparison

Alpha-Lipoic Acid vs Omega-3 (EPA/DHA)

Side-by-side of Alpha-Lipoic Acid and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Alpha-Lipoic Acid

  • Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
  • Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
  • R-ALA enantiomer absorbs 40-100% better than racemic mixtures
  • Activates AMPK; produces small HbA1c reductions in T2DM
  • Plasma half-life ~30 minutes; split dosing or sustained-release is standard
  • Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required

Omega-3 (EPA/DHA)

  • Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
  • REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
  • Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
  • Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
  • Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
  • Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state

Side-by-side

Attribute Alpha-Lipoic Acid Omega-3 (EPA/DHA)
Category supplement supplement
Also known as ALA, thioctic acid, R-ALA, R-lipoic acid fish oil, EPA, DHA, marine omega-3
Half-life (hr) 0.5 48
Typical dose (mg) 600 2000
Dosing frequency 1 to 3 times daily on empty stomach 1 to 2 times daily with food
Routes oral, iv oral
Onset (hr) 0.5 4
Peak (hr) 1 12
Molecular weight 206.33 302.45
Molecular formula C8H14O2S2 C20H30O2 (EPA); C22H32O2 (DHA)
Mechanism Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function.
Legal status Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia
WADA status allowed allowed
DEA / Rx Not scheduled Not scheduled
Pregnancy Insufficient data; precautionary avoidance Recommended at 200 to 600 mg DHA/day for fetal development
CAS 62-46-4 10417-94-4
PubChem CID 864 446284
Wikidata Q161227 Q207688

Safety profile

Alpha-Lipoic Acid

Common side effects

  • nausea
  • abdominal discomfort
  • diarrhea
  • sulfurous odor
  • rash (rare)

Contraindications

  • pregnancy and lactation (insufficient safety data)
  • active insulin autoimmune syndrome predisposition

Interactions

  • insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
  • thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
  • biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
  • iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
  • chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)

Omega-3 (EPA/DHA)

Common side effects

  • fishy aftertaste
  • eructation (fish burps)
  • mild dyspepsia
  • loose stools at high doses

Contraindications

  • fish allergy (use algal omega-3 alternative)
  • active bleeding disorders
  • scheduled surgery (discontinue 5-7 days prior)

Interactions

  • warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
  • aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
  • statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
  • antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)

Which Should You Take?

Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Alpha-Lipoic Acid is the right call when one of the conditionals below applies.

Edge case: Half-lives differ materially (Alpha-Lipoic Acid ~0.5 hr vs Omega-3 (EPA/DHA) ~48 hr). Omega-3 (EPA/DHA) reaches steady state faster; Alpha-Lipoic Acid is easier to dial in if tolerability is uncertain.

Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Alpha-Lipoic Acid only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Alpha-Lipoic Acid and Omega-3 (EPA/DHA)?

Alpha-Lipoic Acid and Omega-3 (EPA/DHA) differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Alpha-Lipoic Acid or Omega-3 (EPA/DHA)?

Alpha-Lipoic Acid half-life is 0.5 hours; Omega-3 (EPA/DHA) half-life is 48 hours.

Can you stack Alpha-Lipoic Acid with Omega-3 (EPA/DHA)?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper